Addictiveness as a risk factor for verbal memory deficit in schizophrenia: a case-control study

  1. Sonia López Lorenzo
  2. Natalia Jimeno Bulnes
  3. Martín. Vargas Aragón
Revista:
Revista española de drogodependencias

ISSN: 0213-7615

Año de publicación: 2021

Título del ejemplar: MONOGRÁFICO: REHABILITACIÓN PSICOSOCIAL DE PERSONAS CON ADICCIONES: HACIA LA RECUPERACIÓN

Número: 46

Páginas: 48-59

Tipo: Artículo

DOI: 10.54108/RED.2021.46.03.004 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista española de drogodependencias

Resumen

Cognitive deficit is one of the main prognostic predictors in schizophrenia, mainly the deficit in verbal memory. The causal relationship between substances use, substance use disorders and psychotic syndrome is probably multidirectional and still is under the possible effect of confusion factors. The Addictiveness in the Psychotic Syndrome Assessment Scale (APSAS) evaluates in a global mode the dimension of adictivity taking in account all these factors: beginning, frequency, length, and intensity. The objective of the study is to know if the dimension of adictivity is associated to memory disorders. A group of psychotic subjects with memory deficits (n = 47) and a control group of psychotic subjects without memory deficits (n = 58) are compared obtaining a major adictivity in the first group. According to our results, the score of APSAS > 55 indicates possible memory deficits. This measuring can provide relevant information on the actual state, evolution and prognose of patients with comorbidity of psychosis and addiction.

Referencias bibliográficas

  • Antoniades, M., Schoeler, T., Radua, J., Valli,I., Allen, P., Kempton, M. J., & McGuire,P. (2018). Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis. Neuroscience and Biobehavioral Reviews 86, 166–175. https://doi.org/10.1016/j.neubiorev.2017.12.001
  • Benedet, M., & Alejandre, M. (2014). TAVEC.Test de Aprendizaje Verbal España-Complutense (TEA (ed.)).
  • Brady, K. T., & Sinha, R. (2005). Co-occurring mental and substance use di -sorders: The neurobiological effects of chronic stress. American Journal of Psychiatry, 162(8), 1483–1493. https://doi.org/10.1176/appi.ajp.162.8.1483
  • Cella, M., Price, T., Corboy, H., Onwumere, J., Shergill, S., & Preti, A. (2020).Cognitive remediation for inpatients with psychosis: a systematic review and meta-analysis. Psychological Medicine, 50(7), 1062-1076. https://doi.org/10.1017/S0033291720000872
  • Deserno, L., Huys, Q. J. M., Boehme, R.,Buchert, R., Heinze, H. J., Grace, A. A.,Dolan, R. J., Heinz, A., & Schlagenhauf,F. (2015). Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making. Proceedings of the National Academy of Sciences ofthe United States of America, 112(5),1595–1600. https://doi.org/10.1073/pnas.1417219112
  • Falkai, P., Rossner, M. J., Schulze, T. G., Ha-san, A., Brzózka, M. M., Malchow, B.,Honer, W. G., & Schmitt, A. (2015).Kraepelin revisited: Schizophrenia from degeneration to failed regeneration.Molecular Psychiatry, 20(6), 671–676.https://doi.org/10.1038/mp.2015.35
  • Fernandez, V. G., Asarnow, R., Narr, K. L.,Subotnik, K. L., Kuppinger, H., Fogelson, D., & Nuechterlein, K. H. (2018).Temporal lobe thickness and verbal memory in first-degree relatives of individuals with schizophrenia. Schizophrenia Research, 199, 221–225. https://doi.org/10.1016/J.SCHRES.2018.02.038
  • Green, A. I. (2007). Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotoxicity Research, 11(1), 33–39. https://doi.org/10.1007/BF03033480
  • Green, A. I., Noordsy, D. L., Brunette, M. F.,& O’Keefe, C. (2008). Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment, 34(1), 61–71. https://doi.org/10.1016/j.jsat.2007.01.008
  • Heckers, S. (2001). Neuroimaging studies ofthe hippocampus in schizophrenia. Hippocampus, 11(5), 520–528. https://doi.org/10.1002/hipo.1068
  • Heinrichs, R. W., & Zakzanis, K. K. (1998).Neurocognitive deficit in schizophrenia:a quantitative review of the evidence. Neuropsychology, 12(3), 426–445.
  • Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M.X., & Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug and Alcohol Dependence, 191, 234-258. https://doi.org/10.1016/j.drugalcdep.2018.07.011
  • Jimeno, N., Jimeno, A., López, M. N., & Vargas, M. L. (1997). A psychopathological study of substance-induced psychoses in a sample of spanish patients. European Addiction Research, 3(4), 173-183.https://doi.org/10.1159/000259175
  • Kay, S. R., Fiszbein, A., & Opler, L. A. (1987).The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/10.1093/schbul/13.2.261
  • Khokhar, J. Y., Dwiel, L. L., Henricks, A. M.,Doucette, W. T., & Green, A. I. (2018). The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophrenia Research, 194, 78–85. https://doi.org/10.1016/j.schres.2017.04.016
  • Krug, A., Stein, F., & Kircher, T. (2020).Cognitive disorders in schizophrenia.Nervenarzt, 91(1), 2–9. https://doi.org/10.1007/s00115-019-00809-8
  • Llinàs-Reglà, J., Vilalta-Franch, J., López-Pousa, S.,Calvó-Perxas, L., Torrents Rodas, D., & Garre-Olmo, J. (2017). The Trail Making Test:Association With Other Neuropsychological Measures and Normative Values for Adults Aged 55 Years and Older From a Spanish-Speaking Population-Based Sample. Assessment, 24(2), 183–196. https://doi.org/10.1177/1073191115602552
  • Lowe, D. J. E., Sasiadek, J. D., Coles, A. S.,& George, T. P. (2019). Cannabis and mental illness: a review. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 107–120. https://doi.org/10.1007/s00406-018-0970-7
  • Pirnia, T., Woods, R. P., Hamilton, L. S., Lyden,H., Joshi, S. H., Asarnow, R. F., Nuechterlein, K. H., & Narr, K. L. (2015). Hippocampal dysfunction during declarative memory encoding in schizophrenia and effects of genetic liability. Schizophrenia Research, 161(2–3), 357–366. https://doi.org/10.1016/j.schres.2014.11.030
  • Rabinowitz, J., Mehnert, A., & Eerdekens,M. (2006). To what extent do the PANSS and CGI-S overlap? Journal of Clinical Psychopharmacology, 26(3),303–307. https://doi.org/10.1097/01.jcp.0000218407.10362.6e
  • Sanz, J., Vargas, M., & Marin, J. (2009). Battery for assessment of neuropsychological status (RBANS) in schizophrenia: a pilot study in the Spanish population *. Acta Neuropsychiatr., 21(1), 18–25. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=ovftj&NEWS=N&AN=00012993-200902000-00005
  • Slade, M., Amering, M., & Oades, L. (2008).Recovery: An international perspective.Epidemiologia e Psichiatria Sociale, 17(2),128–137. https://doi.org/10.1017/S1121189X00002827
  • Solís-Vivanco, R., Rangel-Hassey, F., León-Ortiz, P., Mondragón-Maya, A., Reyes-Madrigal, F., & De La Fuente-Sandoval, C.(2020). Cognitive impairment in nevermedicated individuals on the schizophrenia spectrum. JAMA Psychiatry, 77(5):543-545. https://doi.org/10.1001/jamap-sychiatry.2020.0001
  • Thompson, J. L., Urban, N., Slifstein, M., Xu,X., Kegeles, L. S., Girgis, R. R., Becker-man, Y., Harkavy-Friedman, J. M., Gil,R., & Abi-Dargham, A. (2013). Striataldopamine release in schizophrenia comorbid with substance dependence.Molecular Psychiatry, 18(8), 909–915. https://doi.org/10.1038/mp.2012.109
  • Urits, I., Gress, K., Charipova, K., Li, N., Ber-ger, A. A., Cornett, E. M., Hasoon, J.,Kassem, H., Kaye, A. D., & Viswanath, O.(2020). Cannabis Use and its Association with Psychological Disorders. Psychopharmacology Bulletin, 50(2), 56–67.
  • Vargas Aragón, M. L., López Lorenzo, S., & Jimeno Bulnes, N. (2021). Adictividad:una dimensión independiente en el síndrome psicótico. Presentación de la Escala de Evaluación de la Adictividad en el Síndrome Psicótico (EASP). Revista Española de Drogodependencias, 46(3), pp-pp.https://doi.org/red.2021.46.03.001
  • Vargas, M.L., Lopez, S., del Brio, A. M., Fernandez, M. L., & Franco, M. A. (2009).Neuropsychology in the Differential Diagnosis of Dual Pathology: Schizophrenia and Drugs Abuse/Dependence. European Psychiatry, 24(S1), 1–1. https://doi.org/10.1016/s0924-9338(09)70701-1
  • Vargas, M.L., & Lopez, S. (2010). P03-145- Addiction syndrome in schizophrenia: one independent dimension. European Psychiatry, 25(December 2010),1125. https://doi.org/10.1016/s0924-9338(10)71114-7
  • Vargas, M.L., & Lopez-Lorenzo, S. (2010).Brief Schizophrenia Addiction Scale(BSAS): a pilot study. Schizophrenia Research, 117(2–3), 426–427. https://doi.org/10.1016/j.schres.2010.02.785
  • Winship, I. R., Dursun, S. M., Baker, G. B.,Balista, P. A., Kandratavicius, L., Maia-de-Oliveira, J. P., Hallak, J., & Howland, J. G.(2019). An Overview of Animal Models Related to Schizophrenia. Canadian Journal of Psychiatry, 64(1), 5–17. https://doi.org/10.1177/0706743718773728
Fuente de los datos: Dialnet